0001599298-24-000046.txt : 20240327 0001599298-24-000046.hdr.sgml : 20240327 20240327202703 ACCESSION NUMBER: 0001599298-24-000046 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240326 FILED AS OF DATE: 20240327 DATE AS OF CHANGE: 20240327 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Dhingra Ankur CENTRAL INDEX KEY: 0001849682 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36866 FILM NUMBER: 24793016 MAIL ADDRESS: STREET 1: C/O CAREDX, INC. STREET 2: 1 TOWER PLACE, 9TH FLOOR CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Summit Therapeutics Inc. CENTRAL INDEX KEY: 0001599298 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2882 SAND HILL ROAD STREET 2: SUITE 106 CITY: MENLO PARK STATE: CA ZIP: 94025 BUSINESS PHONE: 650-460-8308 MAIL ADDRESS: STREET 1: 2882 SAND HILL ROAD STREET 2: SUITE 106 CITY: MENLO PARK STATE: CA ZIP: 94025 FORMER COMPANY: FORMER CONFORMED NAME: Summit Therapeutics plc DATE OF NAME CHANGE: 20150219 FORMER COMPANY: FORMER CONFORMED NAME: Summit Corp plc DATE OF NAME CHANGE: 20140205 4 1 wk-form4_1711585608.xml FORM 4 X0508 4 2024-03-26 0 0001599298 Summit Therapeutics Inc. SMMT 0001849682 Dhingra Ankur C/O SUMMIT THERAPEUTICS INC. 2882 SAND HILL ROAD, SUITE 106 MENLO PARK CA 94025 0 1 0 0 Chief Financial Officer 0 Common Stock 2024-03-26 4 P 0 100000 3.75 A 354958 I By Dhingra Family Revocable Trust The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.74 to $3.76 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. /s/ Ankur Dhingra 2024-03-27